Welcome to Entry Card of Lysosomal Enzymes


Details of RareLED ID Assay_1009
Primary information
GENECTSB
NUMBER OF ASSAY212
ASSAY IDs1179618 723768 723767 723766 723765 723764 723763 723762 723761 723760 50286 50267 47812 620709 1343000 292640 292639 292638 292637 292636 292635 292634 292633 292632 1125414 1299797 1299796 1299795 1299794 316335 747458 723769 1258332 50484 50283 50440 744930 620715 620710 528189 460200 344899 292641 746598 410189 364120 312631 264538 257085 257084 47811 1257708 1118860 50468 50437 50282 50281 50289 703173 689081 50487 50466 50461 50285 50265 575659 704616 269482 263485 50290 1253922 1155493 1118763 673911 512111 502276 349077 1058729 747796 703427 646301 370551 365003 360103 339476 331715 321238 315751 314231 314220 309676 308693 308311 293183 290151 288396 282080 273236 271494 270487 269511 268738 268075 266477 263490 262991 262987 261377 260671 257054 256976 255212 254760 247874 242862 242465 242313 242089 241949 241948 240876 240721 239257 238449 238241 2192
Assay Name1. Inhibition of human liver cathepsin B,2. Mixed inhibition of human recombinant cathepsin B endopeptidase activity using Z-Arg-Arg-AMC substrate assessed as inhibition constant for enzyme-substrate-inhibitor complex,3. Uncompetitive inhibition of human recombinant cathepsin B endopeptidase activity using Z-Arg-Arg-AMC substrate assessed as inhibition constant for enzyme-substrate-inhibitor complex,4. Noncompetitive inhibition of human recombinant cathepsin B exopeptidase activity using Abz-Gly-Ile-Val-Arg-Ala-Lys(Dnp)-OH substrate,5. Mixed inhibition of human recombinant cathepsin B exopeptidase activity using Abz-Gly-Ile-Val-Arg-Ala-Lys(Dnp)-OH substrate assessed as inhibition constant for enzyme-inhibitor complex,6. Competitive inhibition of human recombinant cathepsin B exopeptidase activity using Abz-Gly-Ile-Val-Arg-Ala-Lys(Dnp)-OH substrate assessed as inhibition constant for enzyme-inhibitor complex,7. Mixed inhibition of human recombinant cathepsin B exopeptidase activity using Abz-Gly-Ile-Val-Arg-Ala-Lys(Dnp)-OH substrate assessed as inhibition constant for enzyme-substrate-inhibitor complex,8. Mixed inhibition of cathepsin B (unknown origin) endopeptidase activity assessed as inhibition constant for enzyme-inhibitor complex,9. Mixed inhibition of cathepsin B (unknown origin) endopeptidase activity assessed as inhibition constant for enzyme-substrate-inhibitor complex,10. Noncompetitive inhibition of cathepsin B (unknown origin) exopeptidase activity assessed as inhibition constant for enzyme-inhibitor complex,11. Inhibition of Human Cathepsin B,12. Inhibitory activity against recombinant human cathepsin B (cat B) expressed in baculovirus.,13. Compound was evaluated for the inhibition of Cathepsin B,14. Reversible inhibition of human recombinant cathepsin B assessed as formation of fluorescent degradation product AMC using Z-Arg-Arg-AMC as substrate by Michaelis-Menten method,15. Inhibition Assay: Assay buffers consist of 20 mM citric acid, 60 mM disodium hydrogen orthophosphate, 1 mM EDTA, 0.1% CHAPS, 4 mM DTT, pH 5.8 for legumain, 50 mM dihydrogen sodium orthophosphate, 1 mM EDTA, 5 mM DTT, pH 6.25 for cathepsin B and cathepsin Land 100 mM Tris, 0.1% CHAPS, 10% sucrose, 10 mM DTT, pH 7.4 for caspase-3. Concentrations of substrates during the measurement were 10 nM (legumain, cathepsin Land caspase-3) and 50 nM (cathepsin B) and concentration of enzymes were 100 nM for cathepsin Land caspase-3, 270 nM for legumain and 360 nM for cathepsin B. Each enzyme was incubated with inhibitor concentrations ranging from 1 nM to 1 mM in the presence of the substrates.,16. Inhibition of human liver cathepsin B pre-incubated for 17 hrs in non-buffer solution without DTT,17. Inhibition of human liver cathepsin B pre-incubated for 2 hrs in non-buffer solution without DTT,18. Inhibition of human liver cathepsin B pre-incubated for 24 hrs in buffer without DTT,19. Inhibition of human liver cathepsin B pre-incubated for 17 hrs in buffer without DTT,20. Inhibition of human liver cathepsin B pre-incubated for 2 hrs in buffer without DTT,21. Inhibition of human liver cathepsin B pre-incubated for 24 hrs in assay buffer with DTT,22. Inhibition of human liver cathepsin B pre-incubated for 17 hrs in assay buffer with DTT,23. Inhibition of human liver cathepsin B pre-incubated for 2 hrs in assay buffer with DTT,24. Inhibition of human liver cathepsin B,25. Inhibition of human liver cathepsin B,26. Inhibition of human liver cathepsin B using Abz-Gly-Ile-Val-Arg-Ala-Lys(Dnp)-OH as substrate at pH 4.5 incubated for 30 mins measured for 10 mins by photometrical analysis,27. Inhibition of human liver cathepsin B using Cbz-Arg-Arg-pNA as substrate at pH 4.5 incubated for 30 mins measured for 20 mins by photometrical analysis,28. Inhibition of human cathepsin B,29. Inhibition of human liver cathepsin B using Cbz-Arg-Arg-pNA as substrate at pH 6 incubated for 30 mins measured for 20 mins by photometrical analysis,30. Inhibition of cathepsin B,31. Inhibition of cathepsin B (unknown origin) using RR-AMC as substrate after 30 mins by fluorescence assay,32. Mixed inhibition of human recombinant cathepsin B endopeptidase activity using Z-Arg-Arg-AMC substrate assessed as inhibition constant for enzyme-inhibitor complex,33. Biological Assay: Human liver Cathepsin B (Calbiochem) was pre-incubated with test compound at various concentrations for 5 minutes at 37C. The assay was initiated by addition of substrate Z-Arg-Arg-aminomethylcoumarin (Z-R-R-AMC Bacchem) and the final assay conditions were 1.1 nM cathepsin B, 60 uM Z-R-R-AMC, 126 mM sodium potassium phosphate pH 6.0 (Fisher), 0.3 mM EDTA (Omnipure), 2.7 mM DTT (Omnipure), 0.004% BRIJ 35 (Sigma), and 2.0% DMSO (Acros) in a final volume of 200 uL. Test compounds were serially diluted with DMSO and 0.01% BRIJ 35 to include a final concentration range of 20 uM to 10 pM. The reaction was monitored fluorometrically for 5 minutes at 37C. using black 96-well Corning 3686 assay microplates with a Thermo Fluoroskan Ascent FL microplate reader at excitation and emission filter wavelengths of 355 nm and 460 nm, respectively.,34. Inhibitory activity against Cathepsin B,35. Inhibition of human cathepsin B,36. The compound was evaluated for inhibition of cathepsin B from human liver,37. Inhibition of human liver Cathepsin B using Z-Arg-Arg-aminomethylcoumarin as substrate incubated for 5 mins prior to substrate addition measured for 5 mins by fluorometric analysis,38. Mixed-type inhibition of human recombinant cathepsin B assessed as formation of fluorescent degradation product AMC using Z-Arg-Arg-AMC as substrate by Michaelis-Menten method,39. Partial mixed-type inhibition of human recombinant cathepsin B assessed as formation of fluorescent degradation product AMC using Z-Arg-Arg-AMC as substrate by Michaelis-Menten method,40. Inhibition of human liver cathepsin B after 5 mins by microplate reader analysis,41. Inhibition of human liver cathepsin B,42. Inhibition of cathepsin B,43. Inhibition of human liver cathepsin B pre-incubated for 24 hrs in non-buffer solution without DTT,44. Inhibition of recombinant cathepsin-B (unknown origin) using Z-Arg-Arg-AMC as substrate by fluorescence assay,45. Inhibition of cathepsin B in oxygen free condition,46. Inhibition of human liver cathepsin B,47. Inhibition of human liver cathepsin B,48. Inhibition of cathepsin B,49. Inhibitory activity against human cathepsin B expressed in HepG2 cells,50. Inhibitory activity against human cathepsin B,51. Inhibitory activity against Cathepsin B,52. Enzyme Inhibition Assay: Determination of the enzymatic activity of the catalytic domain of human Cathepsin B. This protein is obtained as an inactive enzyme from Sigma, Wiesbaden, Germany (catalog No. C8571).,53. Inhibition of human cathepsin B,54. Inhibitory activity against cathepsin B (catB),55. Inhibitory activity against recombinant human cathepsin B,56. Compound tested for inhibition of human liver cathepsin B,57. Compound tested for inhibition of human liver Cathepsin B,58. Inhibition of human Cathepsin B,59. Activity of human cathepsin B assessed as compound hydrolysis at 50 uM at pH 6.5 in PBS buffer containing 10 mM N-acetylcysteine by RP-HPLC,60. Inhibition of cathepsin B using Z-Phe-Arg-MCA as substrate incubated for 10 mins prior to substrate addition measured after 30 mins by fluorimetric analysis,61. Kinetic parameter (Ki mM) was evaluated for the inactivation of cathepsin B,62. Inhibitory activity using cysteine protease, Cathepsin B with Cbz-Phe-Arg-AMC as substrate.,63. Compound was tested for its inhibitory activity against cathepsin B,64. Equilibrium dissociation constant for the inhibition of human cathepsin B was determined,65. In vitro inhibitory activity against Cathepsin B,66. Inhibition of human CatB after 60 mins fluorescence assay,67. Inhibition of cathepsin-B using Z-Arg-Arg AMC as substrate by fluorescence assay,68. Inhibition of human liver cathepsin B,69. Inhibition of cathepsin B from human brain,70. Inhibitory activity against human Cathepsin B,71. Inhibition of human liver cathepsin B using Z-RR-AMC as substrate after 5 mins by fluorescence assay,72. Inhibition of cathepsin B (unknown origin) using substrate-3 as substrate by fluorescence assay,73. Inhibition of human cathepsin B,74. Inhibition of human liver cathepsin B using Z-R-R-AMC as substrate preincubated with compound for 5 mins measured after 20 mins by fluorescence analysis,75. Inhibition of human liver cathepsin B,76. Inhibition of cathepsin B,77. Binding affinity to cathepsin B treated up to 2 hrs at 37degC by Dixon plot,78. Inhibition of human cathepsin-B using Z-Val-Val-Arg-AMC as substrate up to 20 mins by fluorescence assay,79. Inhibition of human cathepsin-B,80. Inhibition of human recombinant cathepsin-B using Z-Arg-Arg-AMC as substrate preincubated for 15 mins measured after 1 hr by QFRET assay,81. Inhibition of human cathepsin-B using Cbz-Phe-Arg-AMC as substrate by spectrofluorometer analysis,82. Inhibition of human recombinant cathepsin B by fluorescence assay,83. Inhibition of human cathepsin B,84. Inhibition of human recombinant cathepsin B after 10 mins,85. Inhibition of human recombinant cathepsin B,86. Inhibition of human cathepsin B,87. Inhibition of human liver cathepsin B,88. Inhibition of human cathepsin B,89. Inhibition of cathepsin B in human HepG2 cells,90. Inhibition of cathepsin B,91. Inhibition of human cathepsin B,92. Inhibition of human cathepsin B,93. Inhibition of human cathepsin B,94. Inhibition of human recombinant cathepsin B,95. Inhibition of human recombinant cathepsin B,96. Inhibition of cathepsin B,97. Inhibition of human cathepsin B,98. Inhibition of cathepsin B,99. Inhibition of cathepsin B,100. Affinity to cathepsin B,101. Inhibition of human cathepsin B,102. Inhibition of human cathepsin B,103. Inhibition of Cathepsin B,104. Inhibition of human cathepsin B,105. Inhibition of Cathepsin B,106. Inhibition of Cathepsin B,107. Potency against Ca
ACTIVITYSubstance BioActivity: 1 Active, 1 Activity <= 1 µM, 1 Tested Substance BioActivity: 20 Tested Substance BioActivity: 3 Active, 6 Tested Substance BioActivity: 4 Active, 20 Tested Substance BioActivity: 2 Tested Substance BioActivity: 3 Tested Substance BioActivity: 2 Active, 2 Tested Substance BioActivity: 1 Tested Substance BioActivity: 1 Active, 1 Tested Substance BioActivity: 1 Tested Substance BioActivity: 12 Active, 6 Activity <= 1 nM, 12 Activity <= 1 µM, 12 Tested Substance BioActivity: 30 Active, 29 Activity <= 1 µM, 33 Tested Substance BioActivity: 2 Active, 2 Tested Substance BioActivity: 19 Active, 25 Tested Substance BioActivity: 1 Active, 1 Activity <= 1 µM, 4 Tested Substance BioActivity: 1 Active, 1 Tested Substance BioActivity: 1 Active, 1 Tested Substance BioActivity: 1 Active, 1 Tested Substance BioActivity: 1 Active, 1 Activity <= 1 µM, 1 Tested Substance BioActivity: 1 Active, 1 Tested Substance BioActivity: 1 Tested Substance BioActivity: 1 Active, 1 Tested S